Description: ZALTRAP is a cancer drug given with chemotherapy (FOLFIRI) for mCRC patients previously treated with oxaliplatin. See Important Safety Information and full Prescribing Information including Serious Side Effects.
zaltrap (2) metastatic colorectal cancer treatment (2) metastatic colorectal cancer medicine (2)
ZALTRAP, a vascular endothelial growth factor inhibitor, in combination with fluorouracil, leucovorin, irinotecan (FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen.
You or a loved one may be considering therapy with ZALTRAP, also known as ziv-aflibercept, which is an FDA-approved anti-cancer medicine given in combination with a chemotherapy regimen called FOLFIRI (foal-feer-ee) to treat colorectal cancer that has spread. FOLFIRI combines the drugs fluorouracil, leucovorin, and irinotecan. ZALTRAP is an option for people who have had their cancer worsen or have become resistant to the initial therapy used to treat their metastatic colorectal cancer (mCRC).
Those who receive ZALTRAP have been previously treated with a chemotherapy called oxaliplatin (ox-alley-plaht-in).